MedPath

Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity

Not Applicable
Completed
Conditions
Immunity
Interventions
Dietary Supplement: Cauliflower Mushroom extract
Dietary Supplement: Placebo
Registration Number
NCT01736787
Lead Sponsor
Chonbuk National University Hospital
Brief Summary

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cauliflower Mushroom extract on promotion of immunity. The investigators measured promotion of immunity parameters , including Cytotoxicity, Cytokine (IL-4, IL-10, IFN- γ, TNF-α), and CBC (WBC, RBC, Hb, Hct, MCV, MCH, MCHC, PLT), and monitored their blood pressure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Males and females 30-65 years old
  • Weight within ±30% of ideal body weight
  • Able to give informed consent
Exclusion Criteria
  • WBC concentration below 3000 ㎕
  • Allergic or hypersensitive to any of the ingredients in the test products
  • Diagnosed of gastrointestinal disease such as Immune-related diseases, severe hepatic, renal failure, and diabetes
  • History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
  • History of alcohol or substance abuse
  • Participation in any other clinical trials within past 2 months
  • Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
  • Pregnant or lactating women etc.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cauliflower Mushroom extractCauliflower Mushroom extract-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Changes in Cytotoxicity12 weeks

Cytotoxicity was measured in study visit 1(0 week) and visit 3(12 week). cytotoxicity was measured by NK cell activity. Cytotoxicity (%) = (experimental release - spontaneous release) / (maximum release - spontaneous release) x 100

Changes in Cytokine (IL-4, IL-10, IFN- γ, TNF-α)12 weeks

Cytokine (IL-4, IL-10, IFN- γ, TNF-α) was measured in study visit 1(0 week) and visit 3(12 week).

Secondary Outcome Measures
NameTimeMethod
Changes in CBC (WBC, RBC, Hb, Hct, MCV, MCH, MCHC, PLT)12 weeks

CBC (WBC, RBC, Hb, Hct, MCV, MCH, MCHC, PLT) was measured in study visit 1(0 week) and visit 3(12 week).

Trial Locations

Locations (1)

Clinical Trial Center for Functional Foods; Chonbuk National University Hospital

🇰🇷

Jeonju, Jeollabuk-do, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath